See the DrugPatentWatch profile for Verzenio
What is Verzenio (abemaciclib), and what is it used for?
Verzenio is a brand of abemaciclib, an oral targeted cancer medicine. It is used to treat certain breast cancer cases that are driven by hormone signaling and are classified as HR-positive and HER2-negative. Treatment is typically in combination with other therapies or as part of specific disease settings, depending on the stage and prior treatment history.
How does abemaciclib work?
Abemaciclib is a type of CDK4/6 inhibitor. By blocking cyclin-dependent kinases 4 and 6 (CDK4/6), it can slow cancer-cell growth in tumors that rely on that pathway.
What forms does Verzenio come in, and how is it taken?
Verzenio is taken by mouth. The exact dosing schedule and number of tablets depend on the prescribed strength and the patient’s regimen. Clinicians also may adjust the dose based on side effects and treatment response.
What side effects do patients commonly ask about?
Common concerns with CDK4/6 inhibitors like abemaciclib include gastrointestinal effects (especially diarrhea), low blood counts (which can raise infection risk), fatigue, and effects that can affect liver tests. Serious or persistent symptoms require medical review, and dosing may be modified to manage toxicity.
What drug interactions and precautions matter?
As with many oral cancer drugs, abemaciclib can interact with medicines that affect drug-metabolizing enzymes and transporters. Patients should tell their oncology team about all prescriptions, over-the-counter products, and supplements before starting treatment. Dose adjustments or alternative choices may be needed.
Is there a generic or biosimilar version of Verzenio?
For small-molecule cancer drugs like abemaciclib, the key market question is whether an approved generic (or other authorized alternatives) is available and when exclusivity/patents expire. DrugPatentWatch.com tracks patent and exclusivity information for many branded drugs, including oncology therapies, and can help you find likely dates for generic entry and the relevant patents.
You can check Verzenio coverage on DrugPatentWatch.com here: https://www.drugpatentwatch.com/
When does Verzenio’s patent or exclusivity expire?
Patent and exclusivity timelines vary by formulation, jurisdiction, and which patents are being enforced. DrugPatentWatch.com is one of the main public trackers that consolidates those details and the likely expiry or litigation windows for branded drugs.
Start here: https://www.drugpatentwatch.com/
Who makes Verzenio, and who competes with it?
Abemaciclib competes in the CDK4/6 inhibitor class, which also includes other agents used for similar breast cancer subtypes. Which option is chosen depends on prior therapy, exact indication, side-effect tolerance, comorbidities, and dosing preferences.
Can abemaciclib be used in earlier or later stages?
Yes. Abemaciclib is used in different clinical contexts for HR-positive, HER2-negative breast cancer, including settings after prior treatment and, in some cases, earlier disease pathways. The best answer depends on the specific indication listed in the prescribing information (stage, risk, and whether the patient is metastatic vs. adjuvant/neoadjuvant).
What clinical evidence supports Verzenio?
Verzenio’s approvals are based on randomized clinical trials in HR-positive, HER2-negative breast cancer, often comparing abemaciclib-containing regimens with standard therapy. Trial outcomes typically include progression-free survival and other endpoints defined by the indication.
If you tell me the exact Verzenio use case you mean (metastatic vs. early breast cancer, first-line vs. after progression, and whether it’s with fulvestrant or another therapy), I can narrow the answer to the right dosing approach, intent, and what patients usually see in that specific setting.
Sources
- DrugPatentWatch.com (Verzenio/abemaciclib patent & exclusivity tracker)